---
title: A Dose-escalation Study in Subjects With Advanced Malignancies
nct_id: NCT01072266
overall_status: COMPLETED
phase: PHASE1
sponsor: Incyte Corporation
study_type: INTERVENTIONAL
primary_condition: Solid Tumor
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01072266.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01072266"
ct_last_update_post_date: 2017-11-22
last_seen_at: "2026-05-12T06:22:33.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Dose-escalation Study in Subjects With Advanced Malignancies

**Official Title:** A Phase 1, Open-label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB028060 in Subjects With Advanced Malignancies

**NCT ID:** [NCT01072266](https://clinicaltrials.gov/study/NCT01072266)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 45
- **Lead Sponsor:** Incyte Corporation
- **Collaborators:** Novartis Pharmaceuticals
- **Conditions:** Solid Tumor, Advanced Cancer, Metastatic Cancer
- **Start Date:** 2010-01
- **Completion Date:** 2013-01
- **CT.gov Last Update:** 2017-11-22

## Brief Summary

This is an open label, dose escalation study using a 3 + 3 design to determine if INCB028060 (study drug) is safe, well-tolerated and effective in patients with advanced malignancies. Patients will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group is enrolled and may begin to receive study drug. Doses will be escalated unless a dose-limiting toxicity (DLT) is observed in one of three subjects.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Subjects with neoplastic disease refractory to currently available therapies or for which no effective treatment is available
* Subjects with life expectancy of 12 weeks or longer.
* Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

Exclusion Criteria:

* Subjects who received any anti-cancer medications in the 21 days prior to receiving their first dose of study medication or 6 weeks for mitomycin-C or nitrosoureas.
* Subjects with history of brain metastases or spinal cord compression.
* Subjects who have undergone a bone marrow or solid organ transplant.
* Subjects who have had major surgery within 4 weeks prior to study entry or had minor surgical procedure within 7 days prior to initiating treatment.
* Subjects with clinically significant non-healing or healing wounds or subjects with lung tumor lesions with increased likelihood of bleeding
* Subjects with a history of any gastrointestinal condition
```

## Arms

- **INCB028060** (EXPERIMENTAL) — Subjects will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group of patients may be enrolled and receive study drug. The initial cohort will be treated with 10 mg QD. The second cohort will be treated with 20 mg QD. The third cohort will be treated with 50 mg QD. Subsequent cohorts will be treated with two times the dose of the prior cohort to a limited toxicity level.

## Interventions

- **INCB028060** (DRUG) — 10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.

## Primary Outcomes

- **Safety and tolerability will be the primary endpoint and will be assessed by monitoring the frequency, duration, and severity of AEs** _(time frame: Baseline and every 1-2 weeks based on protocol visit schedule until the end of study or early termination visit.)_

## Secondary Outcomes

- **c-MET inhibitory activity determined by the relationship between blood levels of INCB028060 and the percent inhibition of c-MET phosphorylation** _(time frame: Predose, specific hours post-dose on day and Day 15 of Cycle 1.)_

## Locations (2)

- Baltimore, Maryland, United States
- Nashville, Tennessee, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.|baltimore|maryland|united states` — added _(2026-05-12)_
- `locations.|nashville|tennessee|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01072266.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01072266*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*